BioSpace News Archive

KBI Biopharma, Inc., a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park, North Carolina.

Twist Bioscience Corporation today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development.

Zambon today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to colistimethate sodium powder for nebulization solution (CMS I–neb®) for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa.

AcelRx Pharmaceuticals, Inc. today announced an upcoming podium presentation on DSUVIA (sufentanil sublingual tablet, 30 mcg) which will be presented at the annual meeting of The Aesthetic Society®, “The Aesthetic Meeting 2022", held from April 20 -24 at the San Diego Convention Center.

Global healthcare company AmerisourceBergen (AB) announced today its partnership with Chronicled , the administrator of the MediLedger Network, to leverage a new blockchain-powered solution designed to enhance pharmaceutical chargeback accuracy and significantly reduce chargeback rejections.

Despite all the bad news the COVID-19 pandemic brought upon the world, it has helped us gain a better perspective of our readiness to fend off highly contagious diseases.

NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure.

American Laboratory Products Company, Ltd., a specialty in vitro diagnostics company, announced a merger with GeneProof a.s., a leading molecular diagnostics company based in Brno, Czech Republic.

ExThera Medical announces the publication of clinical study data further demonstrating safety in the treatment of critically ill COVID-19 patients with the Seraph® 100 Microbind® Affinity Blood Filter.

Dermata Therapeutics, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $5.0 million of its common stock and warrants, in a private placement priced at-the-market under Nasdaq rules.